CLAREMONT, Calif., Jan. 11, 2007 (PRIME NEWSWIRE) -- Kiwa Bio-Tech Products Group Corporation announces that it has entrusted technical staff from Jinan Ke Long Bo Ao Bio-Tech Co., Ltd. ("Ke Long Bo Ao"), which is affiliated with the Chinese Academy of Medical Sciences, to give technical training on AF-01 Anti-viral products in Dongguan City, Guangdong Province.
In November, 2006, the local government of Dongguan City, Guangdong Province purchased 3 metric tons of AF-01 Anti-viral products as feed additive from Kiwa. Lately, Kiwa entrusted several technical staff from Ke Long Bo Ao to give technical training on AF-01 products in Dongguan. This training mainly focused on the pathogenesis of bird-flu disease, how to prevent it from wide spread among animals, AF-01's anti-viral mechanism, and correct usages to different poultry and livestock.
Miss Yang, who is in charge of the sales of AF-01 products in Dongguan City, Guangdong Province, said: "This technical training and the sales of AF-01 products are perfectly matched with each other. Professional training helps our clients better understand AF-01 products. I believe that our clients will be able to use the products more scientifically after this training; I also hope that we can work together with Kiwa to explore the potential market in Guangdong for AF-01 products in the future."
Mr. Wei Li, Board Chairman and CEO of Kiwa, noted: "Kiwa pays much attention to the after-sale service and technical support all along, and this is the reason why we always commit ourselves to cooperating with top-ranking research institutes in China. Kiwa will give similar technical trainings in other places where AF-01 products are to be sold in order to help our clients better understand and accept this new technology."
About Kiwa Bio-Tech Products Group Corporation
The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development.
For more information about the Company, please visit the Company's website at http://www.kiwabiotech.com.
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.